MX2020007152A - Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos. - Google Patents
Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.Info
- Publication number
- MX2020007152A MX2020007152A MX2020007152A MX2020007152A MX2020007152A MX 2020007152 A MX2020007152 A MX 2020007152A MX 2020007152 A MX2020007152 A MX 2020007152A MX 2020007152 A MX2020007152 A MX 2020007152A MX 2020007152 A MX2020007152 A MX 2020007152A
- Authority
- MX
- Mexico
- Prior art keywords
- amine
- substituted heterocyclic
- methods
- synthesis
- salts
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- -1 heterocyclic heterocyclic compound Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente divulgación se refiere a compuestos heterocíc1icos sustituidos con amina. La presente divulgación también se refiere a composiciones farmacéuticas que contienen estos compuestos y a métodos para tratar un trastorno (por ejemplo, cáncer) mediante la administración de un compuesto heterocíc1ico sustituido con amina desvelado en este documento o una composición farmacéutica del mismo en sujetos con necesidad del mismo. La presente divulgación también se refiere al uso de tales compuestos en investigación u otros fines no terapéuticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762573917P | 2017-10-18 | 2017-10-18 | |
PCT/US2018/056428 WO2019079540A1 (en) | 2017-10-18 | 2018-10-18 | AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020007152A true MX2020007152A (es) | 2020-12-10 |
Family
ID=66173899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007152A MX2020007152A (es) | 2017-10-18 | 2018-10-18 | Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos. |
Country Status (16)
Country | Link |
---|---|
US (2) | US20200247790A1 (es) |
EP (1) | EP3697762A4 (es) |
JP (2) | JP2021500334A (es) |
KR (1) | KR20200101330A (es) |
CN (1) | CN111417628A (es) |
AU (2) | AU2018353122B2 (es) |
BR (1) | BR112020007632A2 (es) |
CA (1) | CA3079273A1 (es) |
CL (1) | CL2020001009A1 (es) |
CO (1) | CO2020005944A2 (es) |
EA (1) | EA202090959A1 (es) |
IL (2) | IL301746B1 (es) |
MA (1) | MA50418A (es) |
MX (1) | MX2020007152A (es) |
SG (1) | SG11202003225YA (es) |
WO (1) | WO2019079540A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018221705B2 (en) | 2017-02-17 | 2022-10-27 | Trevena, Inc. | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
BR112020007593A2 (pt) | 2017-10-18 | 2020-09-24 | Incyte Corporation | derivados de imidazol condensados substituídos por grupos hidróxi terciários como inibidores de pi3k-gama |
CN114249785B (zh) * | 2020-09-23 | 2024-04-05 | 常州方圆制药有限公司 | 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法 |
JP2023546729A (ja) * | 2020-10-27 | 2023-11-07 | トレベナ・インコーポレイテッド | デルタオピオイドモジュレーターの結晶形及び非晶形 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100584832C (zh) * | 2003-09-18 | 2010-01-27 | 诺瓦提斯公司 | 可用于治疗增殖性病症的2,4-二(苯基氨基)嘧啶类 |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
NZ567851A (en) * | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
US9284272B2 (en) * | 2014-03-28 | 2016-03-15 | Abbvie Inc. | Inhibitors of histone methyltransferase G9a |
US9840500B2 (en) * | 2014-06-16 | 2017-12-12 | Fundación Para La Investigación Médica Aplicada | Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases |
MX2016016667A (es) * | 2014-06-23 | 2017-08-21 | Genentech Inc | Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer. |
BR112018071093A2 (pt) * | 2016-04-15 | 2019-01-29 | Epizyme Inc | composto de fórmula, composição farmacêutica, e método para prevenir ou tratar um distúrbio sanguíneo |
JP2020504715A (ja) * | 2016-12-19 | 2020-02-13 | エピザイム,インコーポレイティド | Ehmt2阻害剤としてのアミン置換複素環化合物およびその使用方法 |
WO2018183923A1 (en) * | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
US20210213014A1 (en) * | 2017-10-18 | 2021-07-15 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
-
2018
- 2018-10-18 KR KR1020207013781A patent/KR20200101330A/ko not_active Application Discontinuation
- 2018-10-18 CA CA3079273A patent/CA3079273A1/en active Pending
- 2018-10-18 CN CN201880077022.4A patent/CN111417628A/zh active Pending
- 2018-10-18 SG SG11202003225YA patent/SG11202003225YA/en unknown
- 2018-10-18 BR BR112020007632-5A patent/BR112020007632A2/pt unknown
- 2018-10-18 AU AU2018353122A patent/AU2018353122B2/en active Active
- 2018-10-18 EP EP18869308.9A patent/EP3697762A4/en active Pending
- 2018-10-18 EA EA202090959A patent/EA202090959A1/ru unknown
- 2018-10-18 MA MA050418A patent/MA50418A/fr unknown
- 2018-10-18 US US16/756,565 patent/US20200247790A1/en not_active Abandoned
- 2018-10-18 IL IL301746A patent/IL301746B1/en unknown
- 2018-10-18 JP JP2020521599A patent/JP2021500334A/ja not_active Withdrawn
- 2018-10-18 MX MX2020007152A patent/MX2020007152A/es unknown
- 2018-10-18 WO PCT/US2018/056428 patent/WO2019079540A1/en unknown
-
2020
- 2020-04-15 CL CL2020001009A patent/CL2020001009A1/es unknown
- 2020-04-16 IL IL273974A patent/IL273974B2/en unknown
- 2020-05-15 CO CONC2020/0005944A patent/CO2020005944A2/es unknown
-
2022
- 2022-03-24 US US17/703,155 patent/US20220324851A1/en active Pending
-
2023
- 2023-01-11 JP JP2023002371A patent/JP2023036991A/ja active Pending
-
2024
- 2024-02-22 AU AU2024201165A patent/AU2024201165A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019079540A1 (en) | 2019-04-25 |
KR20200101330A (ko) | 2020-08-27 |
JP2023036991A (ja) | 2023-03-14 |
IL273974B2 (en) | 2023-08-01 |
US20200247790A1 (en) | 2020-08-06 |
CA3079273A1 (en) | 2019-04-25 |
SG11202003225YA (en) | 2020-05-28 |
MA50418A (fr) | 2021-04-07 |
IL301746B1 (en) | 2024-09-01 |
CO2020005944A2 (es) | 2020-07-31 |
AU2024201165A1 (en) | 2024-03-14 |
IL301746A (en) | 2023-05-01 |
IL273974A (en) | 2020-05-31 |
AU2018353122A1 (en) | 2020-06-04 |
CL2020001009A1 (es) | 2020-12-18 |
AU2018353122B2 (en) | 2023-11-23 |
JP2021500334A (ja) | 2021-01-07 |
EP3697762A1 (en) | 2020-08-26 |
EA202090959A1 (ru) | 2020-07-13 |
IL273974B1 (en) | 2023-04-01 |
CN111417628A (zh) | 2020-07-14 |
US20220324851A1 (en) | 2022-10-13 |
BR112020007632A2 (pt) | 2020-09-29 |
EP3697762A4 (en) | 2021-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010947A (es) | Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. | |
MX2019007234A (es) | Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2 y metodos de uso de los mismos. | |
MX2024004332A (es) | Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos. | |
MX2020007152A (es) | Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos. | |
PH12016502132A1 (en) | Aryl-or heteroaryl-substituted benzene compounds | |
NZ706739A (en) | Substituted benzene compounds | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
MX2013011922A (es) | Compuestos de benceno substituido. | |
BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
PH12018500446A1 (en) | Pyridinone dicarboxamide for use as bromodomain inhibitors | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
PH12016502130A1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. | |
EA201991509A1 (ru) | Аминозамещенные гетероциклические соединения в качестве ингибиторов ehmt2 и способы их применения | |
UA110969C2 (uk) | Арил- або гетероарилзаміщені бензольні сполуки та фармацевтична композиція на їх основі | |
TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors |